EPRX
NASDAQ · Biotechnology
Eupraxia Pharmaceuticals Inc
$8.58
+0.20 (+2.39%)
Open$8.37
Previous Close$8.38
Day High$8.72
Day Low$8.37
52W High$12.86
52W Low$7.35
Volume—
Avg Volume69.8K
Market Cap771.11M
P/E Ratio—
EPS$-0.94
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+416.8% upside
Current
$8.58
$8.58
Target
$44.34
$44.34
$25.23
$44.34 avg
$48.95
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 121.08M | 121.80M | 129.11M |
| Net Income | -20,292,332 | -19,070,968 | -17,081,441 |
| Profit Margin | -16.8% | -15.7% | -13.2% |
| EBITDA | -26,386,283 | -29,891,368 | -27,935,877 |
| Free Cash Flow | -23,062,869 | -20,449,670 | -23,278,243 |
| Rev Growth | +21.7% | +19.1% | -8.5% |
| Debt/Equity | 0.16 | 0.18 | 0.19 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |